BidaskClub upgraded shares of Cerus (NASDAQ:CERS) from a strong sell rating to a sell rating in a report published on Friday, January 5th.
Other equities analysts also recently issued research reports about the company. Cowen set a $6.00 price objective on Cerus and gave the stock a buy rating in a report on Thursday, October 5th. Robert W. Baird reiterated a buy rating and set a $5.00 price target on shares of Cerus in a report on Friday, December 1st. Zacks Investment Research upgraded Cerus from a hold rating to a buy rating and set a $4.00 price target on the stock in a report on Wednesday, November 8th. BTIG Research reiterated a neutral rating on shares of Cerus in a report on Friday, December 8th. Finally, Cantor Fitzgerald reiterated an overweight rating and set a $5.00 price target on shares of Cerus in a report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $5.83.
Cerus (NASDAQ:CERS) traded down $0.05 during trading on Friday, hitting $4.32. 526,965 shares of the stock traded hands, compared to its average volume of 717,954. The company has a market capitalization of $504.97, a price-to-earnings ratio of -7.32 and a beta of 1.93. The company has a quick ratio of 3.11, a current ratio of 3.71 and a debt-to-equity ratio of 0.80. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $4.70.
Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. The company had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.14) EPS. research analysts expect that Cerus will post -0.57 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the business. Elk Creek Partners LLC grew its stake in shares of Cerus by 32.3% in the second quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock worth $14,406,000 after acquiring an additional 1,402,106 shares during the last quarter. Ark Investment Management LLC grew its stake in shares of Cerus by 126.5% in the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock worth $4,219,000 after acquiring an additional 938,647 shares during the last quarter. First Midwest Bank Trust Division grew its stake in shares of Cerus by 50.3% in the third quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock worth $2,944,000 after acquiring an additional 360,785 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after acquiring an additional 184,076 shares during the last quarter. Finally, Premier Asset Management LLC acquired a new stake in shares of Cerus in the third quarter worth $348,000. Institutional investors own 55.72% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cerus (NASDAQ:CERS) Upgraded to “Sell” at BidaskClub” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/cerus-cers-upgraded-to-sell-at-bidaskclub.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.